company background image
VVY logo

Vivoryon Therapeutics ENXTAM:VVY Stock Report

Last Price

€0.53

Market Cap

€13.8m

7D

-1.9%

1Y

-96.4%

Updated

27 Mar, 2024

Data

Company Financials +

Vivoryon Therapeutics N.V.

ENXTAM:VVY Stock Report

Market Cap: €13.8m

VVY Stock Overview

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.

VVY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vivoryon Therapeutics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivoryon Therapeutics
Historical stock prices
Current Share Price€0.53
52 Week High€19.56
52 Week Low€0.49
Beta1.62
1 Month Change-93.97%
3 Month Change-93.39%
1 Year Change-96.35%
3 Year Change-96.52%
5 Year Change-77.00%
Change since IPO-97.36%

Recent News & Updates

Recent updates

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

May 04
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 02
Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Jan 26
Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 16
Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

May 10
We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

Mar 11
Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

Jan 14
We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

Shareholder Returns

VVYNL BiotechsNL Market
7D-1.9%4.1%2.9%
1Y-96.4%-1.1%21.7%

Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned -1.1% over the past year.

Return vs Market: VVY underperformed the Dutch Market which returned 21.7% over the past year.

Price Volatility

Is VVY's price volatile compared to industry and market?
VVY volatility
VVY Average Weekly Movement27.6%
Biotechs Industry Average Movement7.4%
Market Average Movement3.7%
10% most volatile stocks in NL Market8.0%
10% least volatile stocks in NL Market2.3%

Stable Share Price: VVY's share price has been volatile over the past 3 months.

Volatility Over Time: VVY's weekly volatility has increased from 16% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199715Frank Weberhttps://www.vivoryon.com

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.

Vivoryon Therapeutics N.V. Fundamentals Summary

How do Vivoryon Therapeutics's earnings and revenue compare to its market cap?
VVY fundamental statistics
Market cap€13.79m
Earnings (TTM)-€26.29m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VVY income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€26.29m
Earnings-€26.29m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VVY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.